A new research has revealed that a unique non-invasive ultrasound method can treat Type 2 diabetes.
Scientists said short bursts of ultrasound targeted at specific nerves clusters in the liver can reduce insulin and glucose levels. The research was conducted on three different animals to treat Type 2 diabetes.
A team led by GE Research and investigators from Yale School of Medicine, UCLA, and the Feinstein Institutes for Medical Research, reported in the Nature Biomedical Engineering journal that a unique non-invasive ultrasound method is designed in the study to stimulate specific sensory nerves in the liver.
Called peripheral focused ultrasound stimulation (pFUS), the technology lets highly targeted ultrasound pulses hit tissues containing nerve endings.
Researchers said: “We used this technique to explore stimulation of an area of the liver called the porta hepatis. This region contains the hepatoportal nerve plexus, which communicates information on glucose and nutrient status to the brain but has been difficult to study as its nerve structures are too small to separately stimulate with implanted electrodes.”
The treatment was successful in three different kinds of animals with Type 2 diabetes, mice, rats, and pigs.
Raimund Herzog, a Yale School of Medicine endocrinologist working on the project explained that if the ongoing clinical trials confirm the research, then “ultrasound neuromodulation would represent an exciting and entirely new addition to the current treatment options for our patients.”
In the study, just three minutes of focused ultrasound each day helped lower the normal blood glucose levels in diabetic animals. Trials on humans are still underway. The technology used to simplify and automate the systems in a way that they target the specific issue in the liver will need to be developed before the treatment is made available. The technology used in the study requires trained technicians but is aimed to be used at home for effective treatment.
Corresponding author and senior biomedical engineer at GE Research, Christopher Puleo, said: “We’re now in the midst of human feasibility trials with a group of type-2 diabetic subjects, which begins our work toward clinical translation. The use of ultrasound could be a game-changer in how bioelectronic medicines are used and applied to disease, such as Type- 2 diabetes, in the future.”
